Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

NCT03393000 is registered in ClinicalTrials.gov with Diffusion Pharmaceuticals Inc as lead sponsor.

NCT NCT03393000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03393000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Lead sponsor
Diffusion Pharmaceuticals Inc
Phase
Phase 3
Overall status
Terminated
Start date
January 16, 2018
Completion date
November 6, 2020
Enrollment
19 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma